[1] NAGASE T, ISHIKAWA K, SUYAMA M, et al. Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro[J]. DNA Res, 1998, 5(5): 277. doi: 10.1093/dnares/5.5.277
[2] ZELLER C, HINZMANN B, SEITZ S, et al. SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer[J]. Oncogene, 2003, 22(19): 2972. doi: 10.1038/sj.onc.1206474
[3] KOCH CA, ANDERSON D, MORAN MF, et al. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins[J]. Science, 1991, 252(5006): 668. doi: 10.1126/science.1708916
[4] CLAUDIO JO, ZHU YX, BENN SJ, et al. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells[J]. Oncogene, 2001, 20(38): 5373. doi: 10.1038/sj.onc.1204698
[5] DAUPHINEE SM, CLAYTON A, HUSSAINKHEL A, et al. SASH1 is a scaffold molecule in endothelial TLR4 signaling[J]. J Immunol, 2013, 191(2): 892. doi: 10.4049/jimmunol.1200583
[6] ZHU YX, BENN S, LI ZH, et al. The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades[J]. J Exp Med, 2004, 200(6): 737. doi: 10.1084/jem.20031816
[7] BEER S, SCHEIKL T, REIS B, et al. Impaired immune responses and prolonged allograft survival in Sly1 mutant mice[J]. Mol Cell Biol, 2005, 25(21): 9646. doi: 10.1128/MCB.25.21.9646-9660.2005
[8] ZHOU N, LIU C, WANG X, et al. Downregulated SASH1 expression indicates poor clinical prognosis in gastric cancer[J]. Hum Pathol, 2018, 74: 83. doi: 10.1016/j.humpath.2018.01.008
[9] XIE J, ZHANG W, ZHANG J, et al. Downregulation of SASH1 correlates with poor prognosis in cervical cancer[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3781.
[10] REN X, LIU Y, TAO Y, et al. Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma[J]. Oncol Lett, 2016, 11(5): 3123. doi: 10.3892/ol.2016.4345
[11] COURCET JB, ELALAOUI SC, DUPLOMB L, et al. Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma[J]. Eur J Hum Genet, 2015, 23(7): 957. doi: 10.1038/ejhg.2014.213
[12] ZHANG J, CHENG R, LIANG J, et al. Lentiginous phenotypes caused by diverse pathogenic genes(SASH1 and PTPN11): clinical and molecular discrimination[J]. Clin Genet, 2016, 90(4): 372. doi: 10.1111/cge.12728
[13] O'BYRNE K, BURGESS J, BOLDERSON E, et al. 16P The overexpression of SASH1 stimulates cell death in lung cancer cells[J]. J Thorac Oncol, 2016, 11(4 Suppl): S62.
[14] SUN C, ZHANG Z, HE P, et al. Involvement of PI3K/Akt pathway in the inhibition of hepatocarcinoma cell invasion and metastasis induced by SASH1 through downregulating Shh-Gli1 signaling[J]. Int J Biochem Cell Biol, 2017, 89: 95. doi: 10.1016/j.biocel.2017.06.006
[15] MENG Q, ZHENG M, LIU H, et al. SASH1 regulates proliferation, apoptosis, and invasion of osteosarcoma cell[J]. Mol Cell Biochem, 2013, 373(1/2): 201. doi: 10.1007/s11010-012-1491-8
[16] NITSCHE U, ROSENBERG R, BALMERT A, et al. Integrative marker analysis allows risk assessment for metastasis in stage Ⅱ colon cancer[J]. Ann Surg, 2012, 256(5): 763. doi: 10.1097/SLA.0b013e318272de87
[17] RIMKUS C, MARTINI M, FRIEDERICHS J, et al. Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer[J]. Br J Cancer, 2006, 95(10): 1419. doi: 10.1038/sj.bjc.6603452
[18] LIN S, ZHANG J, XU J, et al. Effects of SASH1 on melanoma cell proliferation and apoptosis in vitro[J]. Mol Med Rep, 2012, 6(6): 1243. doi: 10.3892/mmr.2012.1099
[19] YANG L, LIU M, GU Z, et al. Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells[J]. Tumour Biol, 2012, 33(6): 2255. doi: 10.1007/s13277-012-0487-z
[20] YANG L, ZHANG H, YAO Q, et al. Clinical Significance of SASH1 Expression in Glioma[J]. Dis Markers, 2015, 2015: 383046.
[21] ZONG W, YU C, WANG P, et al. Overexpression of SASH1 inhibits TGF-β1-induced EMT in gastric cancer cells[J]. Oncol Res, 2016, 24(1): 17. doi: 10.3727/096504016X14570992647203
[22] SUN D, ZHOU R, LIU H, et al. SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway[J]. Int J Clin Exp Pathol, 2015, 8(10): 12276.
[23] ZHOU D, WEI Z, DENG S, et al. SASH1 regulates melanocyte transepithelial migration through a novel Galphas-SASH1-IQGAP1-E-Cadherin dependent pathway[J]. Cell Signal, 2013, 25(6): 1526. doi: 10.1016/j.cellsig.2012.12.025
[24] ZHOU D, KUANG Z, ZENG X, et al. p53 regulates ERK1/2/CREB cascade via a novel SASH1/MAP2K2 crosstalk to induce hyperpigmentation[J]. J Cell Mol Med, 2017, 21(10): 2465. doi: 10.1111/jcmm.13168
[25] ZHOU D, WEI Z, KUANG Z, et al. A novel P53/POMC/Galphas/SASH1 autoregulatory feedback loop activates mutated SASH1 to cause pathologic hyperpigmentation[J]. J Cell Mol Med, 2017, 21(4): 802. doi: 10.1111/jcmm.13022
[26] MARTINI M, GNANN A, SCHEIKL D, et al. The candidate tumor suppressor SASH1 interacts with the actin cytoskeleton and stimulates cell-matrix adhesion[J]. Int J Biochem Cell Biol, 2011, 43(11): 1630. doi: 10.1016/j.biocel.2011.07.012
[27] CHEN H, WANG D, LIU Y. SASH1 inhibits cervical cancer cell proliferation and invasion by suppressing the FAK pathway[J]. Mol Med Rep, 2016, 13(4): 3613. doi: 10.3892/mmr.2016.4946
[28] 张思铭, 马超, 胡樱子, 等. 活体成像技术观察胶质瘤荷瘤鼠中过表达SASH1基因的作用[J]. 交通医学, 2018, 32(1): 1.